Amgen Inc. $AMGN Shares Acquired by Aviso Financial Inc.

19 Aug 2025, 16:34 by Mitch Edgeman · The Markets Daily

Aviso Financial Inc. lifted its position in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) by 3.0% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 4,009 shares of the medical research company’s stock after buying an additional 117 shares during the quarter. Aviso Financial Inc.’s holdings in Amgen were worth $1,249,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. KPP Advisory Services LLC raised its stake in Amgen by 87.1% in the 1st quarter. KPP Advisory Services LLC now owns 5,833 shares of the medical research company’s stock valued at $1,817,000 after purchasing an additional 2,716 shares during the last quarter. Advisor Resource Council acquired a new position in Amgen in the 1st quarter valued at about $1,331,000. DLK Investment Management LLC raised its stake in Amgen by 7.3% in the 1st quarter. DLK Investment Management LLC now owns 20,491 shares of the medical research company’s stock valued at $6,384,000 after purchasing an additional 1,387 shares during the last quarter. Founders Financial Alliance LLC raised its stake in Amgen by 2.7% in the 1st quarter. Founders Financial Alliance LLC now owns 1,577 shares of the medical research company’s stock valued at $491,000 after purchasing an additional 42 shares during the last quarter. Finally, Stratos Investment Management LLC raised its stake in Amgen by 24.8% in the 1st quarter. Stratos Investment Management LLC now owns 21,382 shares of the medical research company’s stock valued at $6,662,000 after purchasing an additional 4,252 shares during the last quarter. Institutional investors and hedge funds own 76.50% of the company’s stock.

Insider Activity

In other Amgen news, SVP Rachna Khosla sold 1,500 shares of the company’s stock in a transaction that occurred on Thursday, June 5th. The stock was sold at an average price of $289.68, for a total value of $434,520.00. Following the transaction, the senior vice president directly owned 8,162 shares of the company’s stock, valued at $2,364,368.16. This represents a 15.52% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 0.76% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

AMGN has been the subject of several analyst reports. Bank of America boosted their target price on shares of Amgen from $252.00 to $261.00 and gave the company an “underperform” rating in a research note on Wednesday, July 23rd. Guggenheim initiated coverage on Amgen in a report on Tuesday, May 20th. They issued a “neutral” rating and a $288.00 price target for the company. Wall Street Zen cut Amgen from a “buy” rating to a “hold” rating in a report on Saturday, August 9th. Morgan Stanley lifted their price target on Amgen from $330.00 to $333.00 and gave the company an “equal weight” rating in a report on Wednesday, August 6th. Finally, Citigroup lifted their price target on Amgen from $305.00 to $310.00 and gave the company a “neutral” rating in a report on Wednesday, August 6th. Two research analysts have rated the stock with a sell rating, twelve have assigned a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $303.76.

Check Out Our Latest Report on Amgen

Amgen Stock Down 1.3%

NASDAQ AMGN opened at $292.62 on Tuesday. The stock has a market cap of $157.54 billion, a PE ratio of 23.93, a P/E/G ratio of 2.55 and a beta of 0.49. Amgen Inc. has a fifty-two week low of $253.30 and a fifty-two week high of $339.17. The business has a 50 day moving average price of $293.35 and a two-hundred day moving average price of $293.15. The company has a quick ratio of 0.98, a current ratio of 1.31 and a debt-to-equity ratio of 7.24.

Amgen (NASDAQ:AMGN – Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The medical research company reported $6.02 earnings per share for the quarter, topping analysts’ consensus estimates of $5.28 by $0.74. The firm had revenue of $9.18 billion during the quarter, compared to analysts’ expectations of $8.86 billion. Amgen had a return on equity of 174.71% and a net margin of 18.96%. Amgen’s quarterly revenue was up 9.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned $4.97 EPS. As a group, sell-side analysts predict that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, September 12th. Shareholders of record on Friday, August 22nd will be given a $2.38 dividend. This represents a $9.52 dividend on an annualized basis and a dividend yield of 3.3%. The ex-dividend date of this dividend is Friday, August 22nd. Amgen’s dividend payout ratio is presently 77.84%.

About Amgen

(Free Report)

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.